Literature DB >> 15913558

Insulin-degrading enzyme degrades amyloid peptides associated with British and Danish familial dementia.

Laura Morelli1, Ramiro E Llovera, Leonardo G Alonso, Blas Frangione, Gonzalo de Prat-Gay, Jorge Ghiso, Eduardo M Castaño.   

Abstract

Familial British dementia (FBD) and familial Danish dementia (FDD) are autosomal dominant disorders characterized by cerebrovascular and parenchymal amyloid deposition and neurofibrillary degeneration. In both conditions, the genetic defects cause the loss of the normal stop codon in the precursor BRI, generating novel 34-residue peptides named ABri and ADan in FBD and FDD, respectively. ABri and ADan show a strong tendency to aggregate into non-fibrillar and fibrillar structures at neutral pH and this property seems to be directly related to neurotoxicity. Here we report that a recombinant insulin-degrading enzyme (rIDE) was capable of degrading monomeric ABri and ADan in vitro more efficiently than oligomeric species. These peptides showed high beta-structure content and were more resistant to proteolysis as compared to the BRI wild-type product of 23 amino acids. Specific sites of cleavage within the C-terminal pathogenic extensions raise the possibility that proteolysis of monomeric soluble precursors by IDE may delay ABri and ADan aggregation in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15913558     DOI: 10.1016/j.bbrc.2005.05.020

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

Review 1.  Hepatic Insulin Clearance: Mechanism and Physiology.

Authors:  Sonia M Najjar; Germán Perdomo
Journal:  Physiology (Bethesda)       Date:  2019-05-01

2.  BRI2 protein regulates β-amyloid degradation by increasing levels of secreted insulin-degrading enzyme (IDE).

Authors:  Ellen Kilger; Anika Buehler; Heidrun Woelfing; Sathish Kumar; Stephan A Kaeser; Amudha Nagarathinam; Jochen Walter; Mathias Jucker; Janaky Coomaraswamy
Journal:  J Biol Chem       Date:  2011-08-26       Impact factor: 5.157

3.  Mechanisms of enzymatic degradation of amyloid Beta microfibrils generating nanofilaments and nanospheres related to cytotoxicity.

Authors:  Keiji Numata; David L Kaplan
Journal:  Biochemistry       Date:  2010-04-20       Impact factor: 3.162

Review 4.  The irreversible binding of amyloid peptide substrates to insulin-degrading enzyme: a biological perspective.

Authors:  Matías B de Tullio; Laura Morelli; Eduardo M Castaño
Journal:  Prion       Date:  2008-05-01       Impact factor: 3.931

5.  Presenilin-1 280Glu-->Ala mutation alters C-terminal APP processing yielding longer abeta peptides: implications for Alzheimer's disease.

Authors:  Gregory D Van Vickle; Chera L Esh; Tyler A Kokjohn; R Lyle Patton; Walter M Kalback; Dean C Luehrs; Thomas G Beach; Amanda J Newel; Francisco Lopera; Bernardino Ghetti; Ruben Vidal; Eduardo M Castaño; Alex E Roher
Journal:  Mol Med       Date:  2008 Mar-Apr       Impact factor: 6.354

6.  New Insights into Epigenetic and Pharmacological Regulation of Amyloid-Degrading Enzymes.

Authors:  Natalia N Nalivaeva; Nikolai D Belyaev; Anthony J Turner
Journal:  Neurochem Res       Date:  2015-09-16       Impact factor: 3.996

7.  beta-Amyloid degradation and Alzheimer's disease.

Authors:  Deng-Shun Wang; Dennis W Dickson; James S Malter
Journal:  J Biomed Biotechnol       Date:  2006

Review 8.  Amyloid-clearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer's disease.

Authors:  Natalia N Nalivaeva; Nikolai D Belyaev; Caroline Kerridge; Anthony J Turner
Journal:  Front Aging Neurosci       Date:  2014-09-17       Impact factor: 5.750

Review 9.  Modulation of Insulin Sensitivity by Insulin-Degrading Enzyme.

Authors:  Carlos M González-Casimiro; Beatriz Merino; Elena Casanueva-Álvarez; Tamara Postigo-Casado; Patricia Cámara-Torres; Cristina M Fernández-Díaz; Malcolm A Leissring; Irene Cózar-Castellano; Germán Perdomo
Journal:  Biomedicines       Date:  2021-01-17

10.  Proteolytically inactive insulin-degrading enzyme inhibits amyloid formation yielding non-neurotoxic aβ peptide aggregates.

Authors:  Matias B de Tullio; Valeria Castelletto; Ian W Hamley; Pamela V Martino Adami; Laura Morelli; Eduardo M Castaño
Journal:  PLoS One       Date:  2013-04-11       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.